Remote Patient Management of CIEDs

NCT ID: NCT03405740

Last Updated: 2025-02-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

1164 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-05-01

Study Completion Date

2025-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a Canadian multicenter randomized controlled trial to assess remote patient management. Patients will be randomized to remote patient management with VIRTUES versus usual care, and will be stratified by RemoteView vs no RemoteView utilization, as well as by center.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Remote monitoring (RM) has been in use for over a decade and is now used in a blended system of in clinic visits and RM to provide CIED follow up. Prior studies have focused on this blended model of follow up. In this study, we propose a paradigm shift in CIED follow up care that is fully remote, supported by a patient-centered communication system permitting patients to have greater understanding of their CIED and its function. Patients would not have to leave their own communities to obtain state-of-the art care for their cardiac condition or their CIED. Given the burgeoning use of CIEDs (ICDs and PMs), the aging population and particularly in Canada where 19% of the inhabitants are in communities classified as 'rural', many have long distances to travel to reach a health care facility, it is of the utmost importance to take full advantage of available and developing technologies to improve CIED follow up beyond current recommendations. During the life of these patients, many issues may arise, such as atrial or ventricular arrhythmias that may result in syncope, stroke or sudden death, need for increased monitoring resulting from device advisories, or minor programming adjustments to improve device performance, or simply the need for enhanced surveillance as the device battery depletes and replacement is anticipated. New technology has become available that not only permits surveillance, but also permits communication back to the patient, and their respective providers regarding the status of these devices. The combination of technologies will result in a total care of CIEDs termed Remote Patient Management - CIED (RPM-CIED). The incorporation of enhanced monitoring capability, along with automatic recalibration of device settings, allows us to develop a new paradigm of remote patient management where after the patient receives their device, they would remain in the care of their local health team ('spokes') and no longer require travel to the specialized device clinics ('hubs') for follow-up. It creates capacity in the specialized centers to focus exclusively on the problematic cases by removing the need for routine checks.

There are two avenues of new technology that will be used in this study:

1. Remote View: this secure, web-based portal facilitates a virtual view of the device programming by the specialist in real-time while the patient is in their local clinic, thus avoiding patient travel to the specialized clinic (hub).
2. VIRTUES (Virtual Integrated Reliable Transformative User-driven E-health System): this portal has been developed by the Cardiac Arrhythmia Network of Canada to allow the patient to receive reports from the remote transmissions of their device.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cardiac Arrhythmia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Remote Patient Management

Patients will be followed by remote monitoring only.

Group Type ACTIVE_COMPARATOR

Remote Patient Management

Intervention Type DEVICE

1. Transmissions will occur at six monthly intervals, with no in-clinic visits. If there is an actionable event on the remote transmission, patients will be seen at their closest community clinic.
2. All patients will be required to follow up with their family physician at least annually, and their cardiologist at least every 2 years.
3. Patients will be contacted by phone at 6 months and 12 months to document their current health status (change in cardiovascular medications, any cardiovascular hospitalizations, in-clinic device checks, or any new cardiovascular testing completed since the last visit)
4. VIRTUES access

Standard of Care

Remote monitoring at 6 month intervals, alternating with yearly in-clinic visits at their usual site.

Group Type PLACEBO_COMPARATOR

Standard of Care

Intervention Type DEVICE

No intervention

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Remote Patient Management

1. Transmissions will occur at six monthly intervals, with no in-clinic visits. If there is an actionable event on the remote transmission, patients will be seen at their closest community clinic.
2. All patients will be required to follow up with their family physician at least annually, and their cardiologist at least every 2 years.
3. Patients will be contacted by phone at 6 months and 12 months to document their current health status (change in cardiovascular medications, any cardiovascular hospitalizations, in-clinic device checks, or any new cardiovascular testing completed since the last visit)
4. VIRTUES access

Intervention Type DEVICE

Standard of Care

No intervention

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients with a Medtronic, Abbott or Boston Scientific defibrillator/CRT-D capable of remote monitoring with Carelink, Merlin or Latitude.
2. Able to provide consent.
3. Age \>/= 18 years

Exclusion Criteria

1. No family physician or general practitioner
2. Inability to be referred to a specialist
3. Currently followed more than every 6 months by a Heart Function Clinic
4. Participation in another randomized clinical trial that impacts outcome
5. Unreliable automated capture verification by device in pacemaker dependent patient
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Cardiac Arrhythmia Network of Canada

OTHER

Sponsor Role collaborator

Abbott Medical Devices

INDUSTRY

Sponsor Role collaborator

Medtronic

INDUSTRY

Sponsor Role collaborator

Ratika Parkash

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Ratika Parkash

Staff Electrophysiologist

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ratika Parkash, MD FRCPC

Role: PRINCIPAL_INVESTIGATOR

Nova Scotia Health Authority

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Foothills Hospital

Calgary, Alberta, Canada

Site Status RECRUITING

Victoria Cardiac Arrhythmia Trials

Victoria, British Columbia, Canada

Site Status RECRUITING

St. Boniface Hospital

Winnipeg, Manitoba, Canada

Site Status NOT_YET_RECRUITING

Saint John Regional Hospital

Saint John, New Brunswick, Canada

Site Status RECRUITING

QEII HSC

Halifax, Nova Scotia, Canada

Site Status RECRUITING

St. Mary's General Hospital

Kitchener, Ontario, Canada

Site Status RECRUITING

London Health Sciences Center

London, Ontario, Canada

Site Status NOT_YET_RECRUITING

Southlake Regional Health Centre

Newmarket, Ontario, Canada

Site Status RECRUITING

Montreal Heart Institute

Montreal, Quebec, Canada

Site Status RECRUITING

Hopital SacreCoeur

Montreal, Quebec, Canada

Site Status RECRUITING

Hopital Laval

Québec, Quebec, Canada

Site Status RECRUITING

Centre Hospitalier Universitaire de Sherbrooke

Sherbrooke, Quebec, Canada

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Canada

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Ratika Parkash, MD FRCPC

Role: CONTACT

902 473 4474

Patricia Theoret

Role: CONTACT

613 866-0698

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Marcello Tonelli

Role: primary

May Woodburn

Role: primary

250-595-0400 ext. 1

Rebecca Fromm

Role: primary

Jessica Gallager

Role: primary

Jennifer Thurlow

Role: primary

902 473-4841

Mary Radyk

Role: primary

Cheryl Litchfield

Role: primary

Annette Jones

Role: primary

519 941 2410

Jean-Claude Tardif

Role: primary

:514 376-3330 ext. 3612

Ann Langlois

Role: primary

Paule Banville

Role: primary

418-656-8711 ext : 2132

Stephanie McMahon

Role: primary

1 844 721-6094

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RP005

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Tachy Prediction Download Study
NCT03402126 COMPLETED
3T MRI CIED Post-Approval Study
NCT02969395 COMPLETED